Last updated on February 2020

Safety and Immunogenicity of mRNA-1653 a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine in Healthy Adults and Children 12-36 Months of Age With Serologic Evidence of Prior Exposure


Brief description of study

This clinical study will assess the safety and immunogenicity of 2 dose levels of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine, in healthy adults (18-49 years of age) and 3 dose levels in children (12-36 months of age) with serologic evidence of prior exposure. The safety profile of the adult cohort will permit enrollment of the pediatric cohort.

Clinical Study Identifier: NCT04144348

Find a site near you

Start Over

Central Research Associates Inc

Birmingham, AL United States
  Connect »

Clinical Research Prime

Idaho Falls, ID United States
  Connect »

MedPharmics

Metairie, LA United States
  Connect »

Meridian Clinical Research

Norfolk, NE United States
  Connect »

Meridian Clinical Research

Binghamton, NY United States
  Connect »

Child Healthcare Associates

Liverpool, NY United States
  Connect »

Child Healthcare Assoc.

Syracuse, NY United States
  Connect »

Sanford Children's Hospital

Sioux Falls, SD United States
  Connect »

Crossroads Clinical Research

Corpus Christi, TX United States
  Connect »

Tekton Research Inc

San Antonio, TX United States
  Connect »

Tanner Clinic

Layton, UT United States
  Connect »